Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Japan to Buy 20 Million Doses of Pfizer COVID Jab, 5 Million from Moderna
July 28, 2023
- Japan Likely to Slash Moderna Vaccine Purchase, Pfizer Single-Sourcing Plan Nixed
July 28, 2023
- Chuikyo Medical Device Pricing Body Calls for Clearer Reimbursement Criteria for SaMDs
July 27, 2023
- Chuikyo Wary of Abolishing Spillover Rule, Positive on Reviewing Market Expansion Re-Pricing
July 27, 2023
- Chuikyo Divided Over Raising Premium Rates for Listed Products, Extending Evaluation Data
July 27, 2023
- Japan OKs FY2024 Budget Ceilings, 520 Billion Yen for Social Security Cost Rise
July 26, 2023
- MHLW Pharma Bureau Chief Eager to Do Everything on Regulation Panel’s Agenda
July 25, 2023
- Label Expansions for Jakavi, Soliris in Line for Approval
July 25, 2023
- Panel on Generic Industry to Boot Up July 31, Report Expected by Fall
July 25, 2023
- Label Updated for ViiV’s 4 HIV Meds to Change Caution for Patients with Renal Dysfunctions
July 24, 2023
- 93 Health Damages Reported for Temcell in Japan: October-March
July 24, 2023
- Japan Might See COVID-19 Spike in Summer: Top Govt Spokesman
July 24, 2023
- Tadayuki Mizutani Tapped as MHLW Director for Pharma Industry Promotion
July 24, 2023
- Label Revisions Ordered for Xocova, Mounjaro to Add New ADR Risks
July 21, 2023
- LDP Policy Panel OKs FY2024 Budget Guidelines, Social Security Wording Unchanged
July 20, 2023
- Japan’s 1st Stelara, G-Lasta Biosimilars Nearing Finish Line
July 18, 2023
- Perjeta/Herceptin SC Combo Up for MHLW Panel Review on July 31
July 18, 2023
- Reflect Price and Wage Hikes in FY2024 Budget Guidelines, Lawmakers Urge
July 18, 2023
- Relief Claims OK’ed for 6 More Deaths Possibly Tied to COVID Jabs
July 18, 2023
- Japan Weighs Adoption of EMA Approach for Nitrosamine Impurities Risk Assessment
July 14, 2023
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…